P023 Clinical Dermatology in Aging People
DESCRIPTION
The number and proportion of people aged 60 years and older in the population is increasing. In 2019, the number of people aged 60 years and older was 1 billion. According the WHO this number will increase to 1.4 billion by 2030. Undoubtedly, dermatologists will be confronted with many more geriatric patients with diseases that are augmented by aging and even the presentation of new entities. In this session we will present facial changes in the mature patient as well as changes of the hair and nails, we will discuss autoimmune skin disease in mature patient as well as challenges in therapeutic approach in this age group.
LEARNING OBJECTIVES
Diagnose different dermatological conditions in mature patients
Evaluate all potential threats when choosing most appropriate therapy with special emphasis on the age of the patient.
Select the best treatment for each condition.
SCHEDULE
10:30 PM
Introduction
Branka Marinovic, MD, PhD, IFAAD
10:35 PM
Special factors to consider in elderly patients with psoriasis
Mark Lebwohl, MD, FAAD
11:00 PM
Autoimmune blistering diseases in elderly patients
Branka Marinovic, MD, PhD, IFAAD
11:20 PM
Q & A
Branka Marinovic, MD, PhD, IFAAD, Mark Lebwohl, MD, FAAD
11:35 PM
What happens with hair as we age
11:55 PM
Mastering systemic therapy in elderly patients
Carmen M Salavastru, MD, PhD, IFAAD
12:15 AM
Q & A
Carmen M Salavastru, MD, PhD, IFAAD
SPEAKERS
Mark Lebwohl, MD, FAAD
Branka Marinovic, MD, PhD, IFAAD
University Hospital Centre Zagreb; School of Medicine University of Zagreb
Natasha Atanaskova Mesinkovska, PhD, MD, FAAD
Carmen M Salavastru, MD, PhD, IFAAD
Carol Davila University of Medicine and Pharmacy, Colentina Clinical Hospital, Bucharest, Romania
SPEAKER DISCLOSURES
Mark Lebwohl, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); AnaptysBio – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Brickell Biotech, Inc – Consultant (1099 relationship)(Honoraria); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Deep Apple Therapeutics – Consultant (1099 relationship)(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); EPI Health – Consultant (1099 relationship)(Honoraria); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); IQVIA – Consultant (1099 relationship)(Honoraria); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Ortho Dermatologics – Investigator(Grants/Research Funding); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);
Branka Marinovic, MD, PhD, IFAAD
No financial relationships exist with ineligible companies.
Natasha Atanaskova Mesinkovska, PhD, MD, FAAD
AbbVie – Investigator(No Compensation Received); Arcutis, Inc. – Investigator(No Compensation Received); Arena Pharmaceuticals – Advisory Board(Honoraria), Investigator(No Compensation Received); Concert Pharmaceuticals – Advisory Board(Honoraria); Eli Lilly – Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Investigator(No Compensation Received); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(No Compensation Received); Merz Aesthetics – Investigator(Grants/Research Funding); Nutrafol – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Carmen M Salavastru, MD, PhD, IFAAD
Axel Springer AG – Other(Patent royalties or other compensation for Intellectual Property Rights); LEO Laboratories Ltd (LEO Pharma) – Other(Other Financial Benefit); Vichy Laboratoires – Advisory Board(Other Financial Benefit);